» Articles » PMID: 22483251

Progression of Aortic Stenosis in Elderly Patients over Long-term Follow Up

Overview
Journal Int J Cardiol
Publisher Elsevier
Date 2012 Apr 10
PMID 22483251
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The natural history of aortic stenosis (AS) in elderly patients remains poorly defined. In an elderly cohort over long-term follow-up, we assessed: 1) rates and predictors of hemodynamic progression and 2) composite aortic valve replacement (AVR) or death endpoint.

Methods: Consecutive Department of Veterans' Affairs patients with AS (>60 years) were prospectively enrolled between 1988 and 1994 (n=239) and followed until 2008. Patients with ≥ 2 trans-thoracic echocardiograms >6 months apart were included in the progression analysis (n=147). Baseline demographics, comorbidities and echocardiography parameters were recorded. Follow-up was censored at AVR/death.

Results: The age of patients was 73 ± 6 years; 82% were male. Baseline AS severity was mild (67%), moderate (23%) and severe (10%). Follow-up was 6.5 ± 4 years (range: 1-17 years). Annualized mean aortic valve gradient progression rates were: mild AS 4 ± 4 mmHg/year; moderate AS 6 ± 5 mmHg/year and severe AS 10 ± 8 mmHg/year (p<0.001). Five-year event-free survival was 66 ± 5%, 23 ± 7% and 20 ± 10% for mild, moderate and severe AS respectively. Progression to severe AS occurred in 35% and 74% of patients with mild and moderate AS respectively. Independent predictors of rapid progression were: baseline AS severity (per grade) (OR 2.6, p=0.001), aortic valve calcification (per grade) (OR 2.1, p=0.01), severe renal impairment (OR 4.0, p=0.04) and anemia (OR 2.3, p=0.05).

Conclusions: In elderly patients, hemodynamic progression of AS is predicted by AS severity, renal function, aortic valve calcification and history of anemia. These factors identify patients at high risk of rapid hemodynamic progression, for whom more frequent clinical and echocardiographic surveillance is advisable.

Citing Articles

Low-Density Lipoprotein Cholesterol, Type 2 Diabetes and Progression of Aortic Stenosis: The RED-CARPET Heart Valve Subgroup Cohort Study.

He J, Xiong Z, Christopher O, Huang Z, Xu C, Liu M Rev Cardiovasc Med. 2024; 25(8):276.

PMID: 39228497 PMC: 11366981. DOI: 10.31083/j.rcm2508276.


Prediction of the Individual Aortic Stenosis Progression Rate and its Association With Clinical Outcomes.

Venema C, van Bergeijk K, Hadjicharalambous D, Andreou T, Tromp J, Staal L JACC Adv. 2024; 3(4):100879.

PMID: 38939659 PMC: 11198185. DOI: 10.1016/j.jacadv.2024.100879.


Unraveling the Enigma of Moderate Aortic Stenosis: Challenges and Future Prospects.

Santangelo G, Tumminello G, Barbieri L, Mallardi G, Faggiano A, Moscardelli S J Clin Med. 2024; 13(12).

PMID: 38930005 PMC: 11204855. DOI: 10.3390/jcm13123478.


Identifying People at High Risk for Severe Aortic Stenosis: Aortic Valve Calcium Versus Lipoprotein(a) and Low-Density Lipoprotein Cholesterol.

Marrero N, Jha K, Razavi A, Boakye E, Anchouche K, Dzaye O Circ Cardiovasc Imaging. 2024; 17(6):e016372.

PMID: 38889215 PMC: 11423705. DOI: 10.1161/CIRCIMAGING.123.016372.


Evidence That Anemia Accelerates AS Progression Via Shear-Induced TGF-β1 Activation: Heyde's Syndrome Comes Full Circle.

Subramani K, Bander J, Chen S, Suarez-Farinas M, Venkatesan T, Subrahmanian S JACC Basic Transl Sci. 2024; 9(2):185-199.

PMID: 38510715 PMC: 10950403. DOI: 10.1016/j.jacbts.2023.09.007.